55th Mexican President and Khiron Life Sciences Corp (CVE:KHRN) Director Vicente Fox on Khiron’s Corporate Strategy
Former Mexican President and current Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) Director Vicente Fox believes the cannabis industry represents a paradigm shift for Mexican society. He stresses that Khiron’s medical focus provides moderation and stability and that the company’s success is measured in patient numbers. Fox was attracted to Khiron’s commitment to social responsibility and he highlights the company’s significant charitable donations as evidence of Khiron’s accountability. He believes this type of corporate governance is essential if the cannabis “gold rush” is going to continue. He also stresses the obligation the company has to its shareholders and emphasizes Khiron’s commitment to capturing the medical, recreational, and cosmeceutical markets in Mexico specifically and Latin America more broadly.
James West: Can we start with what is your role with Khiron Life Sciences?
Vicente Fox: Well, I’m very honored to be now on the board, Board of Directors and I’m very happy with that. This came about when they came to our event in Mexico, the first CannaMexico World Summit on cannabis. We met there and we found out that we’re twin souls. That we not only want this business sector to progress but that we want to be responsible, socially responsible with people. I think that this industry can bring peace and harmony to places like Mexico, to places like Central America, where we have such high levels of violence and that we need back our youth that is being killed in the streets of Mexico, that is being hired by the cartels and we need to rescue them. So, I think this is a paradigmatic change.
James West: Okay. So, then your role with Khiron is to bring medical cannabis to Mexico?
Vicente Fox: Latin America and to participate in discussions and advice for global strategy for Khiron. So, it’s everything is all together on this, on this board responsibilities that I have and yes, we are particularly interested in beginning to work in the Mexican market that already approved medical use but we are yet missing the regulation for that medical use. So, we are waiting urgently for this to happen because Khiron is ready to go aggressively in the Mexican market place of health.
Second, new authorities, new government have been taking a very open and positive position to go after the whole enchilada. So, recreational use will be pretty soon legalized and in a regulation will come forward but up to now Khiron’s priority is medical use. Khiron is very smart in saying the benchmark, the measuring and indicator for my success is the number of patients, not the amount of kilos of marijuana I can produce, not the markets I go to, it’s patience, it’s the customer and it’s bringing solutions to that patients. It’s making sure that you bring a benefit to him not just selling whatever product you have, is that you make sure that you saw a problem or a need that that patient has
James West: So, is the addiction to opiates as a result of big pharma a problem for the Mexican people?
Vicente Fox: The concept is not yet permeated in Mexico. It is not an issue so big that it is here in the state, but at the very end opioids is an excess, is the lack of moderation in consumption. They are not bad products by themselves. Marijuana, cannabis are not bad products to your health. It is a solution when you consume with moderation, when you consume under a prescription and the guidance of somebody that knows about your health; a doctor, a nurse that can help you to consume what is going to be good for you.
So, I think that the great thing about Khiron in this industry is moderation. If you eat sugar more than you should, you will get diabetes. If you drink more alcohol than you should or you could absorb you’re going to die. So, moderation in every industry is most important and that’s why I speak about these standards that Khiron is trying to set in the industry. I’m not here to tell you as much as you can consume until you die, no. Prescription every month, every time you consume so that we administrate correctly something that is going to be good for your health.
James West: And is Khiron bringing a scientific pharmaceutical approach to the production of cannabis products for Latin America?
Vicente Fox: Absolutely yes! Many of the colleagues we work with have a PhD degree, have a master’s degree in science, in health and yes, the research for new products, the effort on quality products and good for your health products is stored in Khiron and it adapts in a way not only to the market, not only to country by country, it adopts region by region and mostly it adopts through you, the individual consumer. Today with technology I can know how you are, I can know how is your health, I can know what you need and I will give what you need and you through technology will be in contact with me; telling me how do you feel what you need. So, it’s a personalized medical health system that you can do today with technology.
James West: So, you were formerly the head of Coca-Cola, the President of Coca-Cola Latin America and to what extent do you envision using lessons from your time as the head of Coca-Cola Latin America to bring to bear on Khiron to help them succeed in the Latin American market place.
Vicente Fox: What you know, I’m 76 now and I joined the Coca-Cola Company when I was 18. So almost 58 years ago. Marketing is the same, is the same. As you produce you have somebody to consume. But now, the tortilla has been turned around. Now, you tell me what you want me to produce, I produce it and I give it to you.
James West: Okay. So, is there a risk that the cartels in Mexico will suffer because of the legalization of cannabis and its distribution through legal channels?
Vicente Fox: Number one yes, they will be worried about losing market share and income. They derive from marijuana cannabis today. In the case of Mexico that money comes from U.S consumption more than Mexican consumption. So as long as United States moves forward to legalize and hopefully nationally the cartels will be weakened because they will get less and less income themselves. The other one, the positive one is what I have witnessed and seen in mature markets like Seattle, like Vancouver, like Holland, like Portugal, like Uruguay, the criminals, the cartels move in a not visible way from crime industry into legal industry.
James West: From the investors perspective, Khiron also started to roll out products in the cosmeceutical area and so, my question on behalf of the investors who I know will watch this will is that is Khiron’s plan to capture both the medical and the recreational but as well as a cosmeceutical market and perhaps consumer packaged goods and in the context of food and beverages, are they to capture all of the opportunities?
Vicente Fox: When Khiron has an obligation with the consumer, the patient, number one. Number two, has an obligation with its employees and its stakeholders and has an obligation with its stockholders to bring return to them. So, it’s a generous company, a humane company, a company thinking about stakeholders, stockholders and employees.
So, I think that this will keep on going because now I’m working with Khiron to expand the market, to expand the revenue, to increase the return but being a socially responsible company, being a socially responsible corporation within the space of cannabis and marijuana because otherwise this gold rush that we have right now, everybody wants to invest in the industry.
Returns suspected 30, 40, 50 percent, maybe 1x, 2x, 3x depending on the way you run the business could go to hell if we don’t act with responsibility, if we don’t act with the values we believe in the ethics that must be part of this industry. If we are not in some way a responsible industry this gold rush can disappear. Many industries have disappeared because they don’t have those values. So, transparency, reliability, ethics, accountability is a must for this industry. And Khiron is going to be the champion of this values because if it’s not I just pronounce and go away. That’s my commitment with the company and that’s the company’s commitment with me.
James West: Okay, that’s great. Thank you very much. That was perfect.
Vicente Fox: My pleasure.
**IMPORTANT! BY VIEWING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
Notice for Forward-Looking Information
Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.
Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to KHIRON’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by KHIRON $100,000 per month for one year as of May 15, 2019 for a newsletter campaign and certain banner ads, of which a portion is spent to produce multi-media content and a portion to the advertising budget targeting investor. In addition, the Company owns 150,000 Restricted Share Units (RSU’s) of KHIRON, and will benefit from its price appreciation. This compensation and our rights ownership in KHIRON is a major conflict with our ability to be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by KHIRON to conduct investor awareness advertising and marketing for KHIRON. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.
SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter owns Restricted Share Units of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR. The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.